PATENT CLAIM ANALYSIS

Application Number: 16023328
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "005900"]

Abstract:
The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.

Claim (Index 1):
A pharmaceutical composition comprising A14E, B16H, B25H, B29K((N \u03b5 -Eicosanedioyl-\u03b3Glu-[2-(2-{2-[2-(2-aminoethoxy)ethoxy]acetylamino}ethoxy)-ethoxy]acetyl)), desB30 human insulin (Compound 1) and semaglutide; and further comprising from about 1 to about 2% (weight/weight) glycerol; from about 45 to about 75 mM phenol; from about 0 to about 19 mM m-cresol; from about 1.5 to about 2.5 moles of zinc ions per six moles of Compound 1; less than about 25 mM sodium chloride; and having a pH value in the range of from 7.2 to 8.0.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 94.0
- Lexical Diversity: 1.44444
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14391510', '15023872', '15121206', '13309134', '12673226']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7700439739300619
- 35 USC 102 Novelty (BERT): 0.5987757967992055
- Combined Prediction Score: 0.7529171562169763
- Mean Citation Score: 301.8040759999999
- Max Citation Score: 350.0893
- Similarity Product: 281.1489299192249

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test